Therapy Areas: Devices
GE Healthcare, SOPHiA Genetics to Collaborate to Match Treatments to Multimodal Patient Data and Cancer Type
9 July 2021 - - US-based GE Healthcare and SOPHiA Genetics have signed a letter of intent to collaborate on advancing cancer care, with the goal of better targeting and matching treatments to each patient's genomic profile and cancer type, helping to ensure the most effective and personalized treatment, the companies said.

The companies aim to develop new artificial intelligence -powered analytics and workflow solutions to serve both the clinical and biopharma markets.

They'll be deploying GE Healthcare's extensive medical imaging and monitoring capabilities and Edison platform-enabled data aggregation with the SOPHiA DDM cloud-based software-as-a-service analytics genomic insights platform and related solutions, which are available in more than 750 hospitals, laboratories and biopharma companies.

GE Healthcare has deep expertise in clinical workflows, deep learning AI algorithms for image reconstruction and image segmentation, analytics and standardization, while SOPHiA Genetics is a pioneer in data-driven medicine.

Their cloud-based software-as-a-service analytics platform uses AI and machine learning to generate actionable insights for clinicians and researchers from complex multimodal datasets.

The companies aim to break down the data silos across instruments and sites that so often delay or even prevent patients from getting the most appropriate treatment both in cancer and in other diseases.

As cases of cancer continue to rise and are predicted to reach 29.5 m new cases per year by 2040, there is a growing demand for data-driven medicine, both for clinical practice and clinical trials.

GE Healthcare is utilizing its Edison platform to integrate data from diverse sources, such as electronic health records and radiology information systems, imaging and other medical device data.

This integrated data can be used to develop and deploy AI enabled solutions to help simplify oncology patient workflows, better understand increasingly complicated clinical patient data, and compare data from patient to patient.

Next-generation sequencing is rapidly becoming a new standard of care in cancer diagnostics, particularly as novel therapies require genomic information to be prescribed in a personalized way. Today, these sets of information and insights are often bespoke and difficult for clinicians to easily and quickly obtain and recall along the patient care journey.

GE Healthcare is the USD 18bn healthcare business of GE (NYSE: GE).

SOPHiA Genetics is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research.

It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.

The SOPHiA DDM Platform and related solutions, products and services are currently used by more than 750 hospital, laboratory and biopharma institutions globally.